Trendlines Group Ltd. · SGX:42T
Trendlines — The Trendlines Group — Investor Presentation (August 2024)
21 slides from Trendlines's investor presentation, August 2024
Slide 1: Investing to improve the human condition
Investing to improve the human condition Medtech & Agrifood Haim Brosh CEO August 2024
Slide 2: Legal disclaimer
Legal disclaimer Important notice This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfo
Slide 3: Who we are
Who we are We have established, built & continue to invest in our broad medtech and agrifood portfolio. Our goal is to achieve significant exits from our portfolio, bringing value to our shareholders. Trendlines is an Israel-headquartered company that trades in Singapore on the SGX (42T) and in the
Slide 4: Strategic partnerships for growth
Strategic partnerships for growth Chairman Vincent Tchenguiz • Librae Holdings is Trendlines’ • Investor in Trendlines’ IPO, • Co-founded venture fund with largest shareholder (29.41%) holding 2.51% Trendlines for innovative agrifood investing • Trendfood has invested $10M in • Investor and acquirer
Slide 5: Leadership
Leadership Haim Brosh Barak Singer CEO and Interim CFO Trendlines Investments Steve Rhodes Israel Founder & Chair Emeritus 20 years’ managerial and financial Extensive investment Trendlines’ Founder; over 40 experience in public knowledge & experience years’ experience, deep and private companies. +
Slide 6: Board of Directors
Board of Directors Nehama Ronen Elka Nir Interim Chair Lead Independent & External Director 20 years’ experience in public companies. 30 years’ experience She was Director in technology General of Israel’s management of Ministry of Environmental public and private Protection companies Sin Boon Ann P
Slide 7: A taste of our portfolio companies
A taste of our portfolio 44 companies * portfolio 16 28 agrifood medtech * including 8 consolidated portfolio companies in Singapore 7
Slide 8: The natural food color revolution
The natural food color revolution A broad-spectrum of healthy plant-based colors produced via Founded 2018; fermentation technology, using baker’s yeast as a biofactory. 23 employees; Phytolon’s high-quality and cost-effective pigments offer value Yokne’am Illit, IL for consumers, the environment an
Slide 9: 4 more agrifood frontrunners
4 more agrifood frontrunners 16 agrifood portfolio companies Biological, environmentally- Celleste Bio has created a Artificial intelligence analytics Orally-administered disease friendly technology to control proprietary ‘cocoa technology’ employing drones for user- prevention for shrimp and fish t
Slide 10: Cryotherapy treatment for urological tissue
Cryotherapy treatment for urological tissue A new ablative approach for the treatment of urological tissue with cryotherapy. Founded 2015 Achievements CEO Eyal Kochavi • Closed US$16.5 million investment round including IP Submitted national strategic partner participation phase and PCT • Ongoing FI
Slide 11: 4 more leading medtech companies
4 more leading medtech companies 28 medtech portfolio companies Incision-free & mesh-free treatment Next-generation aspiration catheter A small, game-changing Miniature implant for spinal for pelvic organ prolapse (POP) office- for treating ischemic stroke. device to prevent preterm birth. stability
Slide 12: Let's look at the numbers
Let's look at the “= trendlines
Slide 13: Portfolio cluster values
Portfolio cluster values Fair Value of Trendlines’ Non-IFRS* Value of Trendlines’ Share Cluster Share (US$'000) (additional information) (US$'000) Aquaculture & Animal Health US$ 2,648 US$ 3,856 Crop Protection US$ 7,612 US$ 14,128 Future Food & Ingredients US$ 11,518 US$ 18,052 Digitization & Robot
Slide 14: H1 2024: Key Financial Metrics
H1 2024: Key Financial Metrics 30 June 2024 31 December 2023 Portfolio value: US$72.3 million US$66.4 million Total Equity: US$76.3 million US$69.1 million NAV per share: US$0.07 (S$0.09) US$0.07 (S$0.09) Net profit US$1.3 million vs US$4.3 million in H1 2023 14
Slide 15: Consolidated condensed report of income (Group)
Consolidated condensed report of income (Group) Consolidated statements of profit or loss (US$’000) Income 30 June 2024 Gain from change in fair value of investments in portfolio companies 4,494 Income from services to portfolio companies 836 Income from contracted R&D services 40 Financial income 8
Slide 16: Consolidated condensed report of income (Group)
Consolidated condensed report of income (Group) Consolidated statements of profit or loss (US$’000) Expenses 30 June 2024 Operating, general and administrative expenses 3,198 Marketing expenses 65 R&D expenses, net 351 Financial expenses 1,484 Total expenses 5,098 Gain before income taxes 1,299 Net
Slide 17: Balance sheet (Group)
Balance sheet (Group) Assets (US$’000) (US$’000) Current assets 30 June 2024 Non-current assets 30 June 2024 Cash and cash Investments in portfolio 6,288 72,268 equivalents companies Short-term bank Accounts and other 87 12 deposits receivables Accounts and other Right-of-use assets 1,942 1,981 rece
Slide 18: Balance sheet (Group)
Balance sheet (Group) Liabilities (US$’000) (US$’000) Current liabilities 30 June 2024 Long-Term liabilities 30 June 2024 Lease liability 343 Loans from the Israel 2,212 Innovation Authority Short-term loan 342 Lease liability 1,368 Trade and other 2,248 Other long-term payables 14 liabilities Defer
Slide 19: Business developments in 2024
Business developments in 2024 • Management changes Following the retirement of Steve Rhodes and Todd Dollinger from their joint position of CEOs in 2023, Haim Brosh was appointed CEO. In February 2024, Steve & Todd retired from their positions as Chairs. Nehama Ronen was appointed Interim Chair. • S
Slide 20: Investing to improve the human condition
Investing to improve the human condition SGX: 42T Haim Brosh, CEO and Interim CFO OTCQX: TRNLY haim@trendlines.com +972.72.260.7000 www.trendlines.com August 2024
Slide 21: Notes and Disclaimer
Notes and Disclaimer The non-IFRS fair value information does not represent any forecast or future performance but serves as an extra aid in evaluating our portfolio companies and investment approaches. The additional information (Non-IFRS value) which, as stated, differs from the IFRS fair value at
The Trendlines Group — Investor Presentation (August 2024) on 6ix